What is Create Medicines?
Create Medicines operates as a specialized biotechnology entity dedicated to the development of in vivo immune programming therapies. Its core innovation lies in a proprietary mRNA-LNP platform designed to engineer immune cells—specifically T cells, NK cells, and myeloid cells—directly within the patient's body. This approach facilitates the creation of scalable, off-the-shelf immunotherapies that aim to reduce the logistical complexity and high costs associated with current CAR-T cell therapies. By enabling programmable immune responses, the company is addressing significant unmet needs in both oncology and autoimmune disease landscapes, aiming to improve patient accessibility and treatment efficacy.
How much funding has Create Medicines raised?
Create Medicines has raised a total of $134M across 2 funding rounds:
Seed
$12M
Series B
$122M
Seed (2019): $12M, investors not publicly disclosed
Series B (2026): $122M led by ARCH Venture Partners, Hatteras Venture Partners, Alexandria, and Newpath Partners
Key Investors in Create Medicines
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists and entrepreneurs to commercialize innovations.
Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm focused on building transformative companies in the biotech, MedTech, and HealthTech sectors, providing both capital and strategic support to visionary founders.
Alexandria
Alexandria Real Estate Equities, Inc. is a real estate investment trust that specializes in the ownership and development of properties for the life sciences industry, supporting research and development entities.
What's next for Create Medicines?
With this major enterprise-level funding, Create Medicines is poised to accelerate its clinical development pipeline. The capital infusion will likely be directed toward advancing its RNA-based CAR approaches through rigorous human trials and expanding its manufacturing capabilities to support repeat-dose administration. As the company transitions from early-stage research to more mature clinical milestones, the focus will remain on validating the safety and scalability of its in vivo platform. Strategic partnerships and continued investment in R&D will be critical as the firm seeks to disrupt the current immunotherapy market and establish a new standard for accessible, high-precision medical interventions.
See full Create Medicines company page
